![]() |
市場調查報告書
商品編碼
1733726
全球乾眼症市場規模(依病因/嚴重程度、人口統計、治療方法、地理分佈和預測)Global Dry Eye Syndrome Market Size By Etiology and Severity, By Demographics, By Treatment Modalities, By Geographic Scope And Forecast |
2024 年乾眼症市場規模價值 62.8 億美元,預計到 2032 年將達到 86.5 億美元,2026 年至 2032 年的複合年成長率為 4.50%。
乾眼症,也稱為角膜結膜炎,是由於淚液無法充分潤滑眼睛而發生的疾病。
乾眼症(DES),也稱為乾燥性角結膜炎,是一種常見的疾病,患者眼睛產生的淚液品質和數量減少,導致各種不適症狀,並可能損害視力。
當潤滑和保護眼球表面的淚膜因淚液分泌不足或淚液品質差而受到破壞時,就會引發這種疾病。導致這種疾病的因素有很多,包括老齡化、潛在的疾病、更年期等荷爾蒙變化、藥物、乾燥空氣或風等環境因素、長時間使用螢幕以及佩戴隱形眼鏡。
DES 的症狀包括搔癢、灼熱、眼內異物感、發紅、視力模糊、眼睛異常流淚以及對光敏感。
如果不及時治療,乾眼症會導致角膜損傷和視力喪失,因此早期診斷和治療對於保持良好的眼睛健康和防止永久性損傷非常重要。
治療乾眼症的治療方法有多種。這些包括人工淚液、皮質類固醇和Cyclosporine等處方藥,有助於淚液的產生。
還有一些衛生產品可以保持眼瞼油腺的健康。淚點塞也可用於阻塞淚液排放管,使淚液在眼球表面停留更久。改變生活方式,例如限制螢幕時間、使用加濕器和避免過敏原也可能有效。隱形眼鏡最適合乾燥的環境。
影響全球乾眼症市場的關鍵市場動態是:
盛行率不斷上升:人口老化、長期使用數位設備、環境因素和全身性疾病導致全球乾眼症的發生率不斷上升。隨著乾眼症盛行率的上升,對有效治療方案的需求也在增加,從而導致市場成長。
提高意識和診斷:由於患者和醫療保健專業人員的認知不斷提高,對乾眼症的診斷正在增加。宣傳宣傳活動、教育活動和篩檢計畫都有助於促進早期發現和早期療育,從而促進乾眼症治療市場的成長。
老年人口不斷增加:淚液的成分和分泌量會隨著年齡的變化而變化,因此老年人特別容易患乾眼症。隨著世界人口的快速老化,乾眼症的盛行率不斷增加,對治療和照護策略的需求也隨之增加。
過度使用螢幕時間和數位裝置:過度使用電腦、平板電腦和智慧型手機等數位裝置會增加乾眼症的風險。長時間使用螢幕會減少眨眼的頻率,刺激眼睛表面並導致蒸發性乾眼症,增加治療的需要。
治療方法技術的發展:眼科技術和藥理學的技術進步導致了新的、耐受性更好、更有效的乾眼症治療方法的發展。創新配方、藥物傳輸系統和醫療設備正在改善乾眼症症狀的管理,並推動市場擴張。
增加研發活動:製藥公司、生技公司和學術機構對研發 (R&D) 的大量投資正在推動乾眼症新療法和治療方法的發展。這些持續的研發工作正在推動市場擴張和技術創新。
轉變為個人化醫療:轉變為個人化醫療也會影響乾眼症的治療。由於乾眼症是一種難以預測的疾病,且每位患者的特徵不同,因此客製化治療越來越受歡迎。個人化治療和聯合用藥正在推動市場成長,因為它們可以提供更好的治療效果並提高患者滿意度。
主要問題
缺乏知識:對乾眼症缺乏認知限制了乾眼症市場的成長。許多人認為眼睛乾澀、刺激和不適等症狀無關緊要或與醫療問題無關,導致這些症狀無法被診斷和治療。
診斷困難:由於 DES 的症狀與其他眼科疾病的症狀相似,因此診斷困難。目前的診斷技術,包括病史採集、眼表染色和淚液分析,通常無法提供必要的敏感性和特異性,導致延遲或錯誤的診斷。
治療方法的複雜性:患者可能會發現很難堅持 DES治療方法,尤其是對於需要頻繁服用和調整生活方式的藥物。成本、感知效果、不便和不適都會影響依從性水準。
特異性和缺乏治療方法:DES 治療的費用對某些人來說是一個重大障礙,特別是如果保險不涵蓋或自付費用過高的話。這樣的價格負擔可能會使經濟困難的患者不願意購買專門的設備、診所內的治療程序和昂貴的處方藥。
監管障礙:監管障礙對新 DES 療法的採用構成了挑戰。監管評估和核准高且耗時。研究新療法的公司必須遵守嚴格的法律要求來確定其療效和安全性,這可能是一個重大挑戰。此類監管要求可能會阻礙新治療方法的推出。
主要趨勢
盛行率和認知度不斷提高:世界人口老化使乾眼症的風險更大。此外,數位化的生活方式導致螢幕時間增加,從而加劇了乾眼症的發生。隨著大眾對乾眼症症狀和治療方法方案的認知不斷提高,將有更多的人被診斷出患有乾眼症,從而擴大市場機會。
強調早期診斷和預防保健:人們一直強調早期發現和治療乾眼症的重要性,預防性眼部護理也變得越來越重要。更簡單、更容易獲得的診斷技術的開發將有助於更早進行診斷並改善患者的治療效果。
創新治療方法:製藥公司不斷開發專門針對乾眼症的新藥物,為患者提供更安全、更有針對性的治療方法。藥物傳輸技術的進步促進了更有效、潤滑更持久的新型眼藥水的開發。抗發炎藥物和神經營養因子等較新的治療方法在治療乾眼症的根本原因方面顯示出希望。
技術進步:遠端醫療諮詢越來越受歡迎,患者可以更輕鬆地找到眼科醫生進行乾眼症評估和治療。在診斷工具中使用人工智慧(AI)可以提高乾眼症檢測的準確性和效率。
個人化醫療:該行業正在走向個體化醫療方法,根據個別患者的特徵和乾眼症類型量身定做治療方案。這種量身定做的策略有可能帶來更有效的疾病管理。
網路零售的興起:網路零售平台的普及使得人們可以輕鬆獲得非處方乾眼症治療藥物,從而影響傳統的分銷管道。此舉使得患者能夠在家中舒適地購買重要治療藥物。
Dry Eye Syndrome Market size was valued at USD 6.28 Billion in 2024 and is projected to reach USD 8.65 Billion by 2032, growing at a CAGR of 4.50% from 2026 to 2032.
Dry eye syndrome, also known as keratoconjunctivitis sicca is a condition that occurs when your tears aren't able to provide adequate lubrication for your eyes.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca, is a common disorder that reduces the quality and number of tears produced by the eyes, causing a variety of unpleasant symptoms and perhaps impairing eyesight.
This disorder develops when the tear film, which lubricates and protects the eye's surface, is disrupted owing to insufficient tear production or poor tear quality. Several factors contribute to this disruption, including aging, underlying medical disorders, hormonal changes such as menopause, drugs, environmental factors like as dry air and wind, prolonged screen time, and contact lens wear.
DES symptoms include a scratchy or burning sensation, a sense of something foreign in the eye, redness, blurred vision, moist eyes as a paradoxical reaction, and light sensitivity.
If left untreated, dry eye can develop and cause corneal damage and vision issues, therefore early diagnosis and treatment are critical for preserving excellent eye health and avoiding consequences.
There are several therapy options available for dry eye conditions. These include artificial tears to supplement tear production, prescription drugs such as corticosteroids, cyclosporine,
These are also used to treat underlying inflammation or increase tear production, and eyelid hygiene items to keep the oil glands in the eyelids healthy. Punctal plugs can also be used to obstruct tear drainage ducts, allowing tears to stay on the eye's surface for an extended period of time. Lifestyle changes, such as limiting screen time, using a humidifier, and avoiding allergens, can all be beneficial. Contact lenses are suited for arid conditions.
The key market dynamics that are shaping the global dry eye syndrome market include:
Growing Prevalence: The increasing frequency of dry eye syndrome worldwide is being pushed by aging populations, prolonged use of digital gadgets, environmental factors, and systemic illnesses. As the prevalence of dry eye conditions rises, so does the demand for effective treatment options, resulting in market growth.
Increasing Awareness and Diagnostics: Increased awareness among patients and medical professionals has resulted in a greater diagnostic rate for dry eye syndrome. Awareness campaigns, educational initiatives, and screening programs all help to promote early detection and intervention, which contributes to the growth of the dry eye therapy market.
Growing Older Population: Because of age-related differences in tear composition and production, the elderly are especially susceptible to dry eye syndrome. As the global population ages fast, the prevalence of dry eye syndrome rises, creating an increased demand for therapies and care strategies.
Extended Screen Time and Digital Device Usage: The frequent use of digital gadgets such as computers, tablets, and smartphones has been linked to an increased risk of dry eye syndrome. Extended screen time reduces blink rates, irritating the eye's surface and resulting in evaporative dry eye, increasing the necessity for therapies.
Technological Developments in Treatment Options: Technological advances in ophthalmic technology and pharmacology have resulted in the creation of novel dry eye treatments that are more tolerable and effective. Innovative medicine formulations, drug delivery systems, and medical devices are improving the management of dry eye symptoms, which is driving market expansion.
Increasing Research and Development Activities: Large investments in research and development (R&D) by pharmaceutical companies, biotechnology corporations, and academic institutions are propelling the development of new therapeutic approaches and treatments for dry eye. This continuing research and development effort is driving market expansion and innovation.
Transition to Personalized Medicine: The transition to customized medicine has an impact on the management of dry eye syndrome. Given the unpredictability of the ailment and the individual characteristics of each patient, customized medicine treatments are gaining popularity. Customized treatments and combination medicines produce better results and increase patient satisfaction, accelerating market growth.
Key Challenges
Lack of Knowledge: Lack of awareness of dry eye syndrome is limiting the growth of the dry eye syndrome market. Many people disregard symptoms such as dryness, irritation, and discomfort as insignificant or unrelated to a medical problem, resulting in underdiagnosis and treatment.
Difficult in Diagnosing: DES is difficult to diagnose since its symptoms coincide with those of other eye disorders. Current diagnostic techniques, like as questionnaires, ocular surface staining, and tear film analysis, frequently lack the required sensitivity and specificity, resulting in a delayed or incorrect diagnosis.
Complexity of Treatment Approaches: Patient commitment to DES treatment regimens can be difficult, particularly for medications that require frequent doses or lifestyle adjustments. Cost, perceived efficacy, inconvenience, and discomfort can all have an impact on adherence levels.
Lack of Specificity and Therapies: For some people, the cost of treating DES is a substantial obstacle, especially if insurance does not cover the therapies or the out-of-pocket payments are prohibitively expensive. This price burden may discourage patients with limited means from purchasing specialized devices, in-office procedures, or expensive prescription drugs.
Regulatory Obstacles: Regulatory hurdles provide challenges to the adoption of new DES treatments. The process of regulatory evaluation and approval is both expensive and time-consuming. Companies researching novel therapeutics must traverse tight legal requirements to establish efficacy and safety, which can be a significant challenge. These regulatory requirements can impede the availability of novel treatments on the market.
Key Trends:
Rising Prevalence and Increasing Awareness: The global aging population poses a substantial risk for dry eye syndrome. Furthermore, our digital lifestyles lead to increased screen time, which adds to the development of dry eyes. As the public becomes more aware of dry eye symptoms and treatment choices, more people are diagnosed, enhancing the market opportunity.
Focus on Early Diagnosis and Preventive Care: There is a rising emphasis on preventive eye care, emphasizing the significance of early detection and treatment of dry eye to avoid problems. The development of simpler and more accessible diagnostic technologies allows for earlier diagnoses, which can improve patient outcomes.
Innovative Treatment Options: Pharmaceutical companies are continually developing new drugs particularly licensed for dry eyes, providing safer and more tailored treatment approaches. Advances in medication delivery technologies are resulting in novel eye drops with higher potency and longer-lasting lubrication. Emerging therapeutics, such as anti-inflammatory medications and neurotrophic factors, show promise in treating the underlying causes of dry eye.
Technological Advancements: Telehealth consultations are gaining popularity, giving patients easier access to ophthalmologists for dry eye evaluation and treatment. The use of artificial intelligence (AI) in diagnostic tools can increase the accuracy and efficiency of dry eye detection.
Personalized Medicine: The industry is shifting toward customized medicine approaches, which adjust treatment programs based on individual patient characteristics and the type of dry eye they have. This tailored strategy has the potential to result in more effective disease management.
Rise in Online Retail: The increasing popularity of online retail platforms allows for easy access to over-the-counter dry eye products, which influences traditional distribution channels. This move enables patients to conveniently purchase critical treatments from the convenience of their own homes.
Here is a more detailed regional analysis of the global dry eye syndrome market:
North America
North America is substantially dominating the dry eye syndrome market and is anticipated to continue its dominance throughout the forecast period owing to the aging population, as older people are more prone to dry eyes.
Furthermore, the increasing use of digital devices lengthens screen time, which might exacerbate symptoms. Environmental factors such as dry air from air conditioning and heating systems contribute significantly to the region's high incidence of dry eye.
North America's healthcare infrastructure is highly developed, with a significant emphasis on implementing innovative technology and treatments. This innovative system enables the use of cutting-edge diagnostic tools and treatment choices for dry eye, ensuring that patients receive the best care possible.
Patients in North America typically have more disposable expenditures, allowing them to access a variety of dry eye remedies. This includes complex and possibly costly solutions including prescription drugs, specialty contact lenses, and novel therapeutic gadgets.
The capacity to afford such treatments helps to better control dry eye symptoms and enhance patient outcomes. Significant public awareness programs in North America have helped the general public understand dry eye conditions better.
These efforts promote early diagnosis and urge people to seek treatment sooner. As a result, there is an increasing need for dry eye treatment solutions, which is driving market growth.
North America is home to numerous large pharmaceutical businesses that play an important role in the dry eye market. Companies like Johnson & Johnson, with products like Acuvue Oasis with HydraMax, and Allergan, recognized for Restasis, are pioneering the development and distribution of dry eye therapies.
Their presence in the region contributes to continued research and innovation in the field. In North America, there is a major emphasis on researching and developing innovative dry eye treatments and technologies.
Pharmaceutical businesses and research organizations are actively attempting to provide more effective therapies, such as novel medication formulations and enhanced delivery systems.
This commitment to innovation guarantees that patients have access to the most recent and effective treatments. While certain dry eye treatments are covered by insurance in North America, there are still obstacles, especially with newer and more specialized drugs. These treatments may have substantial out-of-pocket costs, limiting patient access.
Asia Pacific
Asia Pacific is expected to be the fastest-growing region in the dry eye syndrome market during the forecast period owing to the substantial increase in the aging population. This demographic shift increases the likelihood of dry eye conditions, enlarging the patient pool and driving demand for effective therapies.
Patients in many Asian countries can now afford a wider selection of dry eye therapies thanks to rising disposable incomes. This economic expansion allows for increased healthcare spending, including advanced and potentially more expensive treatment choices for dry eye condition.
Across the Asia Pacific, public awareness campaigns and educational initiatives are increasing knowledge of dry eye symptoms and potential treatment choices. These efforts are critical in encouraging early diagnosis and treatment, which will boost the market.
The dry and dusty conditions found in certain parts of Asia Pacific contribute to the development of dry eye syndrome, driving up market demand. Pollution and seasonal changes are also key factors in aggravating symptoms.
With increased knowledge of eye health issues, there is a greater emphasis on preventive care and early intervention for illnesses such as dry eye syndrome. This proactive approach attempts to reduce the prevalence and impact of dry eye, hence improving general eye health in the population.
The growing use of new technology, such as telemedicine consultations, is increasing access to dry eye experts, especially in rural places. These technology advancements improve the quality and reach of eye care services, hence helping a larger number of patients.
The Global Dry Eye Syndrome Market is segmented based on Etiology and Severity, Demographics, Treatment Modalities, And Geography.
Based on the Etiology and Severity, the market is bifurcated into Evaporative Dry Eye, Aqueous Deficient Dry Eye, and Mixed/Multifactorial Dry Eye. The Evaporative Dry Eye segment is showing significant growth in the dry eye syndrome market owing to the rising prevalence of dry eye disease can be ascribed to variables such as increased screen time, decreased blinking rate, and age-related tear production. The widespread availability of medications such as EvoTears, which target the evaporative kind of dry eye, makes effective therapies more accessible.
Based on the Demographics, the market is bifurcated into Age, Gender, Work, and Lifestyle. The age segment is showing significant dominance in the dry eye syndrome market owing to the substantial association between rising age and decreased tear output. This represents a considerable business opportunity, particularly given the expanding older population. Products such as easy-to-use eye drops and preservative-free formulations are specifically intended to meet the demands of older adults, fueling growth in this market.
Based on the Treatment Modalities, the market is bifurcated into Artificial tears, Anti-inflammatory Agents, Lid Hygiene, and Warm Compresses. The artificial tears segment is showing significant dominance in the dry eye syndrome market as artificial tears are extensively used and provide symptomatic relief for the majority of dry eye conditions by lubricating the ocular surface. As a first-line therapy, they are preferred due to their ease of administration, non-invasive nature, and the availability of several formulations over the counter. Furthermore, the market offers a wide range of artificial tear formulations with varying viscosities and chemicals to fulfill individual requirements.
Based on Geography, the Global Dry Eye Syndrome Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is substantially dominating the dry eye syndrome market and is anticipated to continue its dominance throughout the forecast period owing to the aging population, as older people are more prone to dry eyes. Furthermore, the increased use of digital devices lengthens screen time, which might exacerbate symptoms. Environmental factors such as dry air from air conditioning and heating systems contribute significantly to the region's high incidence of dry eye.
The "Global Dry Eye Syndrome Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Allergan plc (AbbVie, Inc.), Novartis AG, Johnson & Johnson Vision Care, Inc., Bausch Health Companies, Inc., Santen Pharmaceutical Co., Ltd., Alcon Inc. (Novartis AG), Otsuka Pharmaceutical Co., Ltd., Shire plc (Takeda Pharmaceutical Company Limited), Sun Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.